Mana Capital Acquisition (MAAQ) Competitors $3.74 +0.26 (+7.47%) As of 08/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock MAAQ vs. SCLX, CRBP, SKYE, TNYA, IKT, HURA, SAVA, ZNTL, HLVX, and PLRXShould you be buying Mana Capital Acquisition stock or one of its competitors? The main competitors of Mana Capital Acquisition include Scilex (SCLX), Corbus Pharmaceuticals (CRBP), Skye Bioscience (SKYE), Tenaya Therapeutics (TNYA), Inhibikase Therapeutics (IKT), TuHURA Biosciences (HURA), Cassava Sciences (SAVA), Zentalis Pharmaceuticals (ZNTL), HilleVax (HLVX), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical products" industry. Mana Capital Acquisition vs. Its Competitors Scilex Corbus Pharmaceuticals Skye Bioscience Tenaya Therapeutics Inhibikase Therapeutics TuHURA Biosciences Cassava Sciences Zentalis Pharmaceuticals HilleVax Pliant Therapeutics Mana Capital Acquisition (NASDAQ:MAAQ) and Scilex (NASDAQ:SCLX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends. Which has higher valuation and earnings, MAAQ or SCLX? Mana Capital Acquisition has higher earnings, but lower revenue than Scilex. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMana Capital AcquisitionN/AN/AN/AN/AN/AScilex$56.59M2.22-$72.81M-$29.02-0.62 Is MAAQ or SCLX more profitable? Mana Capital Acquisition has a net margin of 0.00% compared to Scilex's net margin of -179.12%. Company Net Margins Return on Equity Return on Assets Mana Capital AcquisitionN/A N/A N/A Scilex -179.12%N/A -109.95% Do institutionals and insiders hold more shares of MAAQ or SCLX? 68.4% of Mana Capital Acquisition shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 7.9% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend MAAQ or SCLX? Scilex has a consensus price target of $455.00, indicating a potential upside of 2,416.59%. Given Scilex's stronger consensus rating and higher possible upside, analysts clearly believe Scilex is more favorable than Mana Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Scilex 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media prefer MAAQ or SCLX? In the previous week, Scilex had 6 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 6 mentions for Scilex and 0 mentions for Mana Capital Acquisition. Mana Capital Acquisition's average media sentiment score of 0.00 beat Scilex's score of -0.03 indicating that Mana Capital Acquisition is being referred to more favorably in the media. Company Overall Sentiment Mana Capital Acquisition Neutral Scilex Neutral SummaryScilex beats Mana Capital Acquisition on 7 of the 10 factors compared between the two stocks. Get Mana Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for MAAQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAAQ vs. The Competition Export to ExcelMetricMana Capital AcquisitionIn Vitro, In Vivo Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$30.39M$30.39M$2.53B$9.82BDividend YieldN/AN/A2.55%4.07%P/E RatioN/AN/A22.1925.12Price / SalesN/AN/A84.11114.01Price / CashN/AN/A23.3759.05Price / BookN/AN/A34.046.18Net IncomeN/AN/A$31.01M$264.89M7 Day Performance8.41%8.41%0.78%4.22%1 Month Performance-9.88%-9.88%1.69%2.02%1 Year Performance784.16%784.16%28.55%24.22% Mana Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAAQMana Capital AcquisitionN/A$3.74+7.5%N/A+784.2%$30.39MN/A0.001Gap UpSCLXScilex2.2007 of 5 stars$15.72-0.9%$455.00+2,794.4%-58.3%$110.32M$56.59M-0.5480News CoverageEarnings ReportCRBPCorbus Pharmaceuticals4.2935 of 5 stars$8.43-6.3%$49.00+481.3%-83.2%$110.30MN/A-1.7740SKYESkye Bioscience1.8644 of 5 stars$3.52-0.8%$16.60+371.6%-30.4%$109.96MN/A-3.3211News CoverageAnalyst ForecastTNYATenaya Therapeutics3.0478 of 5 stars$0.67+0.9%$6.25+834.4%-61.3%$108.09MN/A-0.70110IKTInhibikase Therapeutics2.0344 of 5 stars$1.43-7.7%$6.50+354.5%+36.7%$106.31MN/A-0.546News CoverageHURATuHURA Biosciences1.8831 of 5 stars$2.30-5.3%$12.67+450.7%N/A$106.14MN/A0.00N/ANews CoverageSAVACassava Sciences2.0977 of 5 stars$2.18-0.5%$2.00-8.3%-91.8%$105.79MN/A-1.4530News CoverageEarnings ReportZNTLZentalis Pharmaceuticals1.9018 of 5 stars$1.44-0.7%$8.20+469.4%-50.3%$104.33M$67.43M-0.64160HLVXHilleVax1.7763 of 5 stars$2.07+0.5%$2.00-3.4%+14.9%$103.29MN/A-1.4520News CoveragePLRXPliant Therapeutics3.8938 of 5 stars$1.66-1.2%$8.19+393.2%-87.5%$103.13M$1.58M-0.4990 Related Companies and Tools Related Companies SCLX Alternatives CRBP Alternatives SKYE Alternatives TNYA Alternatives IKT Alternatives HURA Alternatives SAVA Alternatives ZNTL Alternatives HLVX Alternatives PLRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAAQ) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mana Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mana Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access